查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018689

肌萎縮側索硬化症 (ALS) 治療市場：治療方法、類型、治療階段、給藥途徑和分銷管道分類－2026-2032 年全球市場預測

Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肌萎縮側索硬化症 (ALS) 治療市場價值將達到 7.3306 億美元，到 2026 年將成長至 7.8576 億美元，到 2032 年將達到 11.8864 億美元，年複合成長率為 7.14%。

主要市場統計數據
基準年 2025 7.3306億美元
預計年份：2026年 7.8576億美元
預測年份 2032 1,188,640,000 美元
複合年成長率 (%) 7.14%

對 ALS 的臨床和商業性現狀進行簡要概述，以促進戰略優先排序和循證項目決策。

肌萎縮側索硬化症 (ALS) 是臨床醫生、研究人員和相關人員面臨的最複雜的神經退化性疾病之一。此疾病的臨床異質性，涵蓋遺傳性和散發性病因，對傳統的研發模式提出了挑戰，凸顯了臨床試驗設計、生物標記選擇和治療標靶選擇精準性的重要性。因此，決策者必須整合分子標靶、症狀治療和支持療法等方面的見解，以製定連貫的產品和產品組合策略。

治療方法的創新、證據的進步以及醫療保健服務的變革，是如何重新定義 ALS 治療的發展和商業化的？

肌萎縮側索硬化症（ALS）的治療前景正經歷著變革性的轉變，這主要得益於科學進步、監管政策的細微調整以及不斷發展的治療路徑的融合。基因標靶治療和反義寡核苷酸療法正從實驗性工具發展成為具有明確臨床應用前景的候選療法，促使生物製藥公司重新評估其平台投資和合作策略。同時，幹細胞療法的研究也正從臨床前模型推進到早期人體試驗階段，安全性、給藥途徑和病患選擇正成為決定臨床成功與否的關鍵因素。

評估美國關稅政策變更對 2025 年神經系統藥物價值鏈供應鏈、生產和取得的影響。

貿易和關稅政策的變化對複雜的藥品供應鏈的影響遠不止成本上漲那麼簡單。美國2025年前後的關稅格局變化，對生產策略、採購和定價的韌性提出了嚴峻的挑戰。許多用於神經系統藥物的活性成分和特殊輔料都來自全球各地，進口關稅的提高可能會加劇投入成本的波動。為了應對這項挑戰，各機構正在重新審視供應商多元化、近岸外包以及多源採購合約等方案，以維持供應的連續性並降低貿易政策變化帶來的風險。

以細分為重點的綜合分析，將治療方法、患者亞群、給藥途徑和分銷管道與其臨床和商業性意義聯繫起來。

了解市場需求和臨床應用需要採用細分觀點，將治療方法與患者亞群、疾病階段、給藥途徑和通路相匹配。基於治療方法，市場可分為藥物和治療方法兩大類。藥物治療方法包括Dextromethorphan/奎尼丁、Edaravone、Riluzole和托福生，而治療方法則包括基因療法和幹細胞療法。每種療法都有其獨特的臨床特徵、證據要求和給藥途徑。這種基於治療方法的細分凸顯了小分子對症藥物和神經保護化合物傾向於沿用現有的海外通路，而基因療法和細胞療法則需要專門的給藥環境和長期安全性監測。

對區域趨勢的比較分析概述了主要地區的法規、臨床研究和准入框架如何影響 ALS 治療的開發和商業化。

區域趨勢對肌萎縮側索硬化症（ALS）治療的調節路徑、臨床試驗可行性和准入框架有顯著影響。在美洲，監管機構和支付系統對申請設計和報銷談判有著強大的影響力，而成熟的研究網路則支持在檢驗新機制的臨床試驗中快速招募患者。此外，美洲集中了許多優秀的醫療中心，能夠提供專業的鞘內和靜脈注射注射療法，而綜合醫療保健系統在協調多學科診療方面發揮著至關重要的作用。

競爭與合作的動態揭示了投資組合策略、製造夥伴關係以及對病人參與的投資如何影響 ALS 治療的成功。

肌萎縮側索硬化症（ALS）治療領域的競爭格局呈現出多元化的特點，既有成熟的神經系統疾病治療產品組合，也有專注於生物技術創新的創新企業，還有致力於開發先進治療方法的合約研究機構。大型製藥企業和生技公司正積極推動以疾病分子機制為標靶的平台型療法，而小規模的專業公司則專注於特定適應症、基於生物標記的隊列研究或新型給藥方案。這種多樣性為策略聯盟、授權協議和共同開發契約創造了機遇，從而將科學專長與商業性規模相結合。

採取實際有效的策略措施，協調研發、供應鏈和進入工作，降低專案風險，加速病患獲得治療。

產業領導者必須將策略投資與實際情況結合，才能在管控風險的同時掌握治療與商業性機會。優先考慮臨床開發團隊與以支付方為導向的證據團隊之間的合作至關重要，這能確保在專案設計早期就整合試驗終點、自然病程對照和健康經濟學模型。這種協調一致有助於減少後續的准入障礙，並在產品上市時支持強力的價值溝通。

混合方法研究框架結合了對專家的初步訪談和二手證據的整合，並採用嚴格的三角檢驗，檢驗了治療和操作方面的見解。

本分析的研究途徑結合了對同儕審查文獻、監管指南和公共臨床試驗註冊庫的系統性回顧，以及針對臨床、監管、供應鏈和商業領域的專家訪談。對神經科、臨床試驗首席研究員、衛生經濟學家和供應鏈高管的訪談，為新興治療方法趨勢、管理挑戰和支付方期望提供了定性檢驗。輔助研究則整合了科學出版物、監管簡報文件和已發布的治療指南，以闡明治療機制和臨床終點。

從科學、營運和支付方考慮因素的交匯點出發，對將 ALS 治療的進展轉化為短期內患者可及性起著至關重要的作用，提供了全面的觀點。

肌萎縮側索硬化症（ALS）的治療格局正處於轉折點，分子層面的精準治療、新型給藥方式以及不斷演變的證據預期相互交匯，重塑著藥物研發和市場准入策略。基因標靶治療治療和細胞療法的進步有望真正改變特定患者群體的疾病進程，而症狀治療和監測技術的改進則提升了疾病各個階段患者的生活品質。然而，要實現這些機遇，需要嚴格整合臨床證據、生產能力以及面向支付方的價值論證。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肌萎縮側索硬化症（ALS）治療市場（依治療方法分類）

  • 藥物治療
    • Dextromethorphan/奎尼丁
    • Edaravone
    • Riluzole
    • 託費爾森
  • 治療方法
    • 基因治療
    • 幹細胞療法

第9章 肌萎縮側索硬化症（ALS）治療市場：按類型分類

  • 遺傳性肌萎縮性側索硬化症
  • 散發性肌萎縮性側索硬化症

第10章：肌萎縮側索硬化症（ALS）治療市場（依治療階段分類）

  • 晚期治療
  • 早期治療
  • 中期治療

第11章 肌萎縮側索硬化症（ALS）治療市場：依給藥途徑分類

  • 鞘內腔
  • 靜脈
  • 口服

第12章 肌萎縮側索硬化症 (ALS) 治療市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房

第13章 肌萎縮側索硬化症（ALS）治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肌萎縮側索硬化症（ALS）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肌萎縮側索硬化症（ALS）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國肌萎縮側索硬化症（ALS）治療市場

第17章：中國肌萎縮側索硬化症（ALS）治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AB Science SA
  • Alector, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • Ascend Pharmaceuticals LLC
  • AstraEureka Pharmaceuticals
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Cipla Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Dewpoint Therapeutics, Inc.
  • DR. REDDY'S LABORATORIES LIMITED
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline PLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurimmune AG
  • Novartis AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Treeway BV
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 733.06 million in 2025 and is projected to grow to USD 785.76 million in 2026, with a CAGR of 7.14%, reaching USD 1,188.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 733.06 million
Estimated Year [2026] USD 785.76 million
Forecast Year [2032] USD 1,188.64 million
CAGR (%) 7.14%

Concise contextualization of the ALS clinical and commercial landscape to inform strategic prioritization and evidence-driven program decisions

Amyotrophic lateral sclerosis represents one of the most complex neurodegenerative diseases confronting clinicians, researchers, and commercial stakeholders. The clinical heterogeneity of the condition, spanning familial and sporadic etiologies, challenges conventional development paradigms and elevates the importance of precision in trial design, biomarker selection, and therapeutic targeting. As a result, decision-makers must synthesize insights across molecular therapies, symptomatic agents, and supportive care to frame coherent product and portfolio strategies.

Recent advances in antisense modalities, targeted antioxidants, and repurposed symptomatic combinations have shifted clinical conversations from purely supportive management toward disease-modifying intent. Alongside these clinical developments, shifting regulatory expectations and heightened scrutiny on evidence of functional benefit have prompted sponsors to calibrate endpoints and invest in longitudinal natural history datasets. Consequently, commercial leaders must balance near-term access and reimbursement pathways for symptomatic products with longer-term investment in high-cost, high-complexity modalities.

This executive summary distills the most consequential trends, segmentation insights, regional dynamics, and actionable recommendations for organizations operating across the ALS treatment continuum. The goal is to equip executives with a concise, evidence-driven narrative that supports prioritization, risk mitigation, and the design of commercially viable development programs in a rapidly evolving therapeutic landscape.

How converging therapeutic innovation, evidence evolution, and care delivery transformation are redefining development and commercialization for ALS treatments

The ALS treatment landscape is undergoing transformative shifts driven by converging scientific advances, regulatory nuance, and evolving care pathways. Gene-targeted approaches and antisense oligonucleotides have matured from experimental tools into clinical candidates with clear translational potential, prompting biopharma organizations to re-evaluate platform investments and collaboration strategies. At the same time, stem cell therapy research has progressed from preclinical models to early human studies that emphasize safety, route of administration, and patient selection as critical determinants of translational success.

Parallel to therapeutic innovation, real-world evidence generation and digital biomarkers are reshaping how clinical benefit is demonstrated. Remote monitoring technologies and objective functional metrics are increasingly incorporated into trial protocols to capture granular changes in disease trajectory, enabling more sensitive detection of therapeutic signals. Payers and health technology assessment bodies are responding by seeking evidence that links surrogate improvements to meaningful patient-centric outcomes, thus influencing trial designs and post-approval evidence commitments.

Commercially, the distribution and administration complexities of advanced therapies are redefining channel strategies. Intrathecal and intravenous modalities necessitate specialized infusion centers and care coordination, which elevates the role of hospital pharmacies and integrated health systems in enabling patient access. Consequently, manufacturers are establishing center-of-excellence programs and partnering with clinical networks to streamline delivery, support adherence, and reduce logistical friction. Taken together, these shifts underscore an industry pivot toward integrated development and commercialization approaches that account for the entire patient journey from diagnosis to long-term follow-up.

Assessing the supply chain, manufacturing, and access implications of evolving United States tariff policies for neurological therapeutic value chains in 2025

Policy shifts in trade and tariffs have implications for complex therapeutic supply chains that extend beyond simple cost increments, and the unfolding tariff landscape in the United States for 2025 introduces material considerations for manufacturing strategy, procurement, and pricing resilience. Many active pharmaceutical ingredients and specialty excipients used in neurological therapeutics are sourced globally, and increased import duties can amplify input cost volatility. In response, organizations are reassessing supplier diversification, nearshoring options, and multi-sourcing agreements to preserve continuity of supply and mitigate exposure to trade policy shocks.

Beyond raw material costs, tariffs can influence the location of critical production steps such as fill-finish operations, cold chain logistics, and specialized biologics manufacturing. These operational shifts can extend lead times and increase the capital intensity of ensuring regulatory-compliant manufacturing footprints. Consequently, sponsors may accelerate investments in domestic manufacturing capabilities or long-term contractual commitments with contract manufacturing organizations that can absorb policy-driven margin pressure while guaranteeing capacity.

Importantly, the cumulative impact of tariffs also cascades into pricing and access strategies. Payers and procurement entities are likely to scrutinize price trajectories, particularly for high-cost, specialty therapies. Manufacturers may need to adopt more sophisticated value dossiers and risk-sharing arrangements to maintain formulary access under tightening budget constraints. In short, the tariffs scenario for 2025 reinforces the need for proactive supply chain risk management, flexible sourcing, and integrated commercial planning that anticipates regulatory, operational, and payer responses to increased cost pressures.

A segmentation-focused synthesis that links treatment modalities, patient subgroups, administration routes, and distribution channels to clinical and commercial implications

Understanding demand and clinical adoption requires a segmentation-aware perspective that aligns therapeutic modalities with patient subgroups, stages of disease, routes of administration, and distribution pathways. Based on treatment, the landscape divides into medication and therapies, where medication modalities include dextromethorphan/quinidine, edaravone, riluzole, and tofersen, while therapy approaches span gene therapy and stem cell therapy, each presenting distinct clinical profiles, evidence expectations, and delivery requirements. This treatment-based segmentation highlights that small-molecule symptomatic agents and neuroprotective compounds tend to follow established outpatient distribution channels, whereas gene-based and cellular therapies drive requirements for specialized administration settings and long-term safety surveillance.

Based on type, the dichotomy between familial ALS and sporadic ALS matters considerable for both development strategy and trial enrollment. Familial forms often support targeted molecular approaches with genetically defined mechanisms, enabling more precise patient selection and potentially more rapid proof-of-concept studies. Sporadic ALS, by contrast, demands broader population strategies and biomarker-driven stratification to address etiologic heterogeneity and demonstrate generalizability.

Based on treatment stage, early stage treatment, mid stage treatment, and advanced stage treatment each call for tailored endpoints, supportive care integrations, and risk-benefit considerations. Early stage interventions emphasize slowing progression and preserving function, necessitating sensitive outcome measures and proactive patient identification. Mid stage management focuses on symptom modulation and maintaining quality of life, while advanced stage treatments prioritize palliative integration, respiratory support coordination, and caregiver enablement.

Based on route of administration, intrathecal, intravenous, and oral delivery options shape clinical workflow, monitoring requirements, and adherence considerations. Intrathecal and intravenous routes often require hospital-based administration and specialized training, whereas oral therapies facilitate decentralized care but may encounter challenges with pharmacokinetics and central nervous system penetration. Based on distribution channel, hospital pharmacies and retail pharmacies play complementary roles where hospital pharmacies are central to specialty infusion and intrathecal administration while retail pharmacies support outpatient medication continuity and symptomatic management. Synthesizing these segmentation lenses enables stakeholders to map therapeutic attributes to operational capabilities, payer expectations, and patient access pathways.

Comparative regional dynamics outlining how regulatory, clinical research, and access frameworks across major geographies influence ALS development and commercialization

Regional dynamics materially shape regulatory pathways, clinical trial feasibility, and access frameworks for ALS treatments. In the Americas, regulatory authorities and payer systems exert strong influence on dossier design and reimbursement negotiations, while well-established research networks support rapid patient recruitment for trials that test novel mechanisms. The Americas also host concentrated centers of excellence that enable delivery of specialized intrathecal and intravenous therapies, and integrated health systems play a pivotal role in coordinating multidisciplinary care.

In Europe, Middle East & Africa, stakeholders navigate a mosaic of regulatory frameworks and payer models that require tailored evidence strategies and localized market access planning. Centralized regulatory procedures in some jurisdictions can expedite approvals for certain therapeutics, whereas heterogeneous reimbursement pathways across countries demand flexible pricing and risk-sharing models. Additionally, regional clinical networks and academic consortia are increasingly collaborating on multi-country trials that leverage shared natural history datasets and harmonized endpoints.

Asia-Pacific presents diverse development opportunities and operational considerations; several countries are investing in biotech infrastructure and clinical capacity, which opens pathways for local manufacturing partnerships and regional clinical studies. However, differences in diagnostic practices, genetic epidemiology, and healthcare financing require sponsors to adapt trial protocols and value communication strategies. Across all regions, cross-border collaboration, data sharing, and alignment on real-world evidence standards are becoming essential to support global development programs and ensure equitable patient access to emerging therapeutics.

Competitive and collaborative dynamics that reveal how portfolio strategies, manufacturing partnerships, and patient engagement investments shape ALS therapeutic success

The competitive environment in ALS therapeutics is characterized by a mix of established neurological portfolios, specialist biotech innovators, and contract organizations enabling advanced modality development. Leading pharmaceutical and biotech entities are advancing platform approaches that target molecular drivers of disease, while smaller specialists focus on niche indications, biomarker-driven cohorts, or novel delivery solutions. This diversity generates opportunities for strategic alliances, licensing arrangements, and joint development agreements that align scientific expertise with commercial scale.

Partnerships between developers and specialized contract manufacturers or service providers are increasingly central to managing the complexity of biologic and cellular product manufacturing. These collaborations help translate early-stage proof-of-concept into scalable clinical production while addressing regulatory expectations for quality and traceability. Additionally, payer-facing capabilities and global market access expertise are differentiators for companies seeking broad adoption, prompting acquisitions and collaborations that integrate clinical development with health economics and outcomes research capabilities.

Competition also extends to patient engagement and diagnostic ecosystems; organizations investing in patient registries, remote monitoring platforms, and early diagnostic initiatives can accelerate trial enrollment and strengthen real-world evidence generation. Consequently, companies that combine robust R&D pipelines with deep commercial integration, manufacturing resilience, and patient-centric evidence strategies are best positioned to navigate the complexity of the ALS treatment landscape.

Practical, high-impact strategic measures that align development, supply chain, and access initiatives to de-risk programs and accelerate patient access

Industry leaders must align strategic investments with operational realities to capture therapeutic and commercial opportunities while managing risk. First, prioritize integration between clinical development and payer evidence teams so that trial endpoints, natural history comparators, and health economic models converge early in program design. This alignment reduces downstream access friction and supports robust value communication at launch.

Second, diversify sourcing and manufacturing arrangements to enhance supply chain resilience in the face of trade policy shifts and input scarcity. Near-term tactics include multi-sourcing key intermediates, securing capacity in geographically distributed facilities, and investing in flexible fill-finish capabilities that accommodate modality-specific requirements. Third, invest in partnerships that expand diagnostic reach and patient registry participation to shorten enrollment timelines and improve the representativeness of trial populations, particularly for familial and genetically defined cohorts.

Fourth, design commercialization plans that reflect route-of-administration realities by ensuring hospital systems and specialty pharmacies are engaged early to build treatment pathways and center-of-excellence networks. Fifth, adopt adaptive evidence-generation strategies that combine randomized data with well-structured real-world evidence and digital biomarker endpoints, enabling iterative payer dialogue and post-approval data commitments. Collectively, these actions create a resilient playbook for translating scientific breakthroughs into accessible treatments while managing regulatory, operational, and commercial risk.

A mixed-methods research framework combining primary expert engagement and secondary evidence synthesis with rigorous triangulation to validate therapeutic and operational insights

The research approach underpinning this analysis combined a structured review of peer-reviewed literature, regulatory guidance, and public clinical trial registries with targeted expert interviews across clinical, regulatory, supply chain, and commercial domains. Primary engagement with neurologists, clinical trial investigators, health economists, and supply chain executives provided qualitative validation of emerging modality trends, administration challenges, and payer expectations. Secondary research synthesized scientific publications, regulatory briefing documents, and published treatment guidelines to contextualize therapeutic mechanisms and clinical endpoints.

Data triangulation was used to reconcile differing perspectives and to identify consistent themes regarding evidence needs, delivery constraints, and regional differences. Where possible, methodological rigor was preserved by cross-checking interview insights against documented clinical trial designs and public regulatory decisions. The analysis intentionally emphasized mechanistic and operational factors over proprietary market estimates to ensure the findings remain broadly applicable and decision-focused.

Limitations of the methodology include variability in public disclosure across early-stage programs, heterogeneity in regional regulatory processes, and evolving trade policy contexts that may change after the analysis cut-off. To mitigate these limitations, the study prioritized themes supported by multiple independent sources and sought corroboration from clinical and commercial experts with direct ALS experience.

Summative perspective on the intersecting scientific, operational, and payer considerations that will determine near-term translation of ALS treatment advances into patient access

The ALS therapeutic landscape is at an inflection point where molecular precision, novel delivery modalities, and evolving evidence expectations converge to reshape development and access strategies. Advances in gene-targeted and cellular approaches offer real potential for altering disease trajectory for selected patient cohorts, while improvements in symptomatic agents and monitoring technologies enhance quality-of-life management across disease stages. However, realizing these opportunities requires disciplined alignment of clinical evidence, manufacturing capacity, and payer-focused value demonstration.

Operational risks such as supply chain fragility, tariff-driven cost pressures, and the logistical demands of intrathecal and intravenous administration necessitate proactive mitigation and strategic investment. In parallel, segmentation-aware development that differentiates between familial and sporadic forms, maps stage-specific therapeutic objectives, and matches routes of administration to distribution capabilities will be critical to optimizing trial design and commercial rollout. Ultimately, organizations that couple scientific innovation with purposeful engagement across clinical networks, payers, and delivery partners will be best positioned to translate therapeutic advances into sustainable patient access and long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 8.1. Medication
    • 8.1.1. Dextromethorphan/Quinidine
    • 8.1.2. Edaravone
    • 8.1.3. Riluzole
    • 8.1.4. Tofersen
  • 8.2. Therapies
    • 8.2.1. Gene Therapy
    • 8.2.2. Stem Cell Therapy

9. Amyotrophic Lateral Sclerosis Treatment Market, by Type

  • 9.1. Familial ALS
  • 9.2. Sporadic ALS

10. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage

  • 10.1. Advanced Stage Treatment
  • 10.2. Early Stage Treatment
  • 10.3. Mid Stage Treatment

11. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration

  • 11.1. Intrathecal
  • 11.2. Intravenous
  • 11.3. Oral

12. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Amyotrophic Lateral Sclerosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyotrophic Lateral Sclerosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyotrophic Lateral Sclerosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Amyotrophic Lateral Sclerosis Treatment Market

17. China Amyotrophic Lateral Sclerosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AB Science SA
  • 18.6. Alector, Inc.
  • 18.7. Amylyx Pharmaceuticals, Inc.
  • 18.8. Apotex Inc.
  • 18.9. Aquestive Therapeutics, Inc.
  • 18.10. Ascend Pharmaceuticals LLC
  • 18.11. AstraEureka Pharmaceuticals
  • 18.12. Biogen Inc.
  • 18.13. BrainStorm Cell Limited
  • 18.14. Cipla Limited
  • 18.15. CorestemChemon Inc.
  • 18.16. Coya Therapeutics, Inc.
  • 18.17. Cytokinetics, Incorporated
  • 18.18. Dewpoint Therapeutics, Inc.
  • 18.19. DR. REDDY'S LABORATORIES LIMITED
  • 18.20. F. Hoffmann-La Roche Ltd
  • 18.21. Genervon Biopharmaceuticals, LLC
  • 18.22. GlaxoSmithKline PLC
  • 18.23. Implicit Bioscience Ltd.
  • 18.24. Ionis Pharmaceuticals, Inc.
  • 18.25. ITF Pharma, Inc.
  • 18.26. Kringle Pharma, Inc.
  • 18.27. Mitsubishi Tanabe Pharma Corporation
  • 18.28. Neurimmune AG
  • 18.29. Novartis AG
  • 18.30. ONO PHARMACEUTICAL CO., LTD.
  • 18.31. Orion Corporation
  • 18.32. Orphazyme A/S
  • 18.33. Otsuka Pharmaceutical Co., Ltd.
  • 18.34. Pfizer, Inc.
  • 18.35. Sanofi SA
  • 18.36. Sun Pharmaceutical Industries Ltd
  • 18.37. Teva Pharmaceutical Industries Ltd.
  • 18.38. Treeway B.V.
  • 18.39. Viatris Inc.
  • 18.40. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 139. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 163. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 171. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 173. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)